Analyst firms · Morgan Stanley · BSX
Morgan Stanley BSX price target and rating history
Boston Scientific Corporation (BSX) · Health Care
Morgan Stanley rates Boston Scientific Corporation (BSX) Overweight with a $58 price target, as of its latest action on May 30, 2023. It has published 3 rating actions on BSX since July 2021, including 0 upgrades and 0 downgrades. Across 5 firms with a BSX price target in the last 12 months, the median target is $50.
- Current rating
- Overweight
- Price target
- $58
- Median target, all firms
- $50
- Actions on BSX
- 3
Morgan Stanley price target on BSX
Every Morgan Stanley rating on BSX
- May 30, 2023
- Feb 3, 2022
- Jul 28, 2021
How other firms rate BSX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| TD Cowen | Hold | $46 | Oct 30, 2026 |
| Oppenheimer | Perform | Oct 29, 2026 | |
| Barclays | Equal Weight | $48 | Oct 7, 2026 |
| Citigroup | Neutral | $50 | Sep 17, 2026 |
| Argus Research | Hold | Jul 31, 2026 | |
| Wolfe Research | Peer Perform | May 29, 2026 | |
| Wells Fargo | Equal Weight | $55 | May 28, 2026 |
| Raymond James | Outperform | $88 | Mar 30, 2026 |
Questions about Morgan Stanley and BSX
- What is Morgan Stanley's price target for BSX?
- Morgan Stanley's latest stated price target for Boston Scientific Corporation (BSX) is $58, from its action on May 30, 2023.
- What is Morgan Stanley's rating on BSX?
- Morgan Stanley rates BSX Overweight, a bullish rating, as of May 30, 2023.
- When did Morgan Stanley last change its view on BSX?
- On May 30, 2023, Morgan Stanley resumes coverage at Overweight, price target $58.
- How does Morgan Stanley's BSX target compare with other analysts?
- Across 5 firms with a BSX price target in the last 12 months, the median target is $50.
More BSX rating histories
All Morgan Stanley ratingsBSX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.